PDS Biotechnology Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
30.4%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.50next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly21.7MTarget: Sufficient liquidity to fund operations into 2027
Research and Development (R&D) Expenses Quarterly3.5MTarget: Controlled spending to optimize cash runway
Net Loss Quarterly7.3MTarget: Narrowing losses through operational efficiency
Watch Items
- VERSATILE-003 Phase 3 Trial EnrollmentTrigger: Restarting enrollment under the amended protocolAction: Monitor patient recruitment rates and clinical site activation
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 for 30 consecutive business daysAction: Regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive business days before August 24, 2026
- Debt Refinancing and Promissory Note AmortizationTrigger: YA II PN, Ltd. $6,000,000 Promissory Note maturity in June 2027Action: Track cash outflows for note amortization and utilization of the $50,000,000 ATM equity facility
Research as of 19 Jun 2026